Atlas Trials

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Clinical trial NCT03959293 · UNKNOWN

Trial details

NCT number
NCT03959293
Sponsor
Federation Francophone de Cancerologie Digestive
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric AdenocarcinomaGastric Cancer
Start date
2019-07-17
Primary completion
2022-03-15
Enrollment
107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.